Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

Washington: Researchers have identified a previously overlooked protein that helps regulate appetite and energy use in the ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue ...

Oklahoma reports declines in adult and childhood obesity, citing state initiatives and community programs for healthier lifestyles.

Pfizer PFE stock has declined around 3% this week. On Dec. 16, the company announced its financial guidance for 2026, which ...

Discover why Pfizer (PFE) remains a compelling income opportunity with a 7% yield, robust cash flow, and long-term growth ...

GLP-1s improved outcomes in patients with heart failure with preserved ejection fraction, with or without obesity, but those ...

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

The perception of GLP-1s — and the people who use them — is getting better, but work still must be done to avoid stigma.

Are pickles bad for blood pressure? Yes, eating pickles every day increase your blood sodium levels and raise blood pressure, putting you at risk of hypertension.

The number of US adults living with heart failure has more than doubled over the past three decades, mostly due to the rising ...

If our leaders heed this call, we can help ensure that obesity treatments remain tools of healing, not shortcuts to danger.